menu search

PCSA / Processa Pharmaceuticals to Present at the ThinkEquity Conference

Processa Pharmaceuticals to Present at the ThinkEquity Conference
HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that CEO George Ng will present an updated corporate overview at the ThinkEquity Conference. The conference is being held on October 19, 2023 at the Mandarin Oriental Hotel in New York. Read More
Posted: Oct 13 2023, 13:08
Author Name: GlobeNewsWire
Views: 091951

PCSA News  

Processa Pharmaceuticals to Present at the ThinkEquity Conference

By GlobeNewsWire
October 13, 2023

Processa Pharmaceuticals to Present at the ThinkEquity Conference

HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage p more_horizontal

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

By GlobeNewsWire
August 10, 2023

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

HANOVER, MD, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage p more_horizontal

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

By GlobeNewsWire
April 28, 2023

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

HANOVER, MD, April 28, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage more_horizontal

Heatwurx Inc. (PCSA) Upgraded to Buy: Here's What You Should Know

By Zacks Investment Research
April 6, 2023

Heatwurx Inc. (PCSA) Upgraded to Buy: Here's What You Should Know

Heatwurx Inc. (PCSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive more_horizontal

Processa Pharmaceuticals' (PCSA) CEO David Young on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 14, 2022

Processa Pharmaceuticals' (PCSA) CEO David Young on Q1 2022 Results - Earnings Call Transcript

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jim Stanker – Chief Fina more_horizontal

Processa Pharmaceuticals' (PCSA) CEO David Young on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 30, 2022

Processa Pharmaceuticals' (PCSA) CEO David Young on Q4 2021 Results - Earnings Call Transcript

Processa Pharmaceuticals' (PCSA) CEO David Young on Q4 2021 Results - Earnings Call Transcript more_horizontal

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST

By GlobeNewsWire
March 23, 2022

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST

HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing p more_horizontal

Processa Pharmaceuticals' (PCSA) CEO David Young on Q3 2021 Results - Earnings Call Transcript

By Seeking Alpha
November 11, 2021

Processa Pharmaceuticals' (PCSA) CEO David Young on Q3 2021 Results - Earnings Call Transcript

Processa Pharmaceuticals' (PCSA) CEO David Young on Q3 2021 Results - Earnings Call Transcript more_horizontal


Search within

Pages Search Results: